Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s32687
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited